{"product_id":"bayesian-designs-for-phase-i-ii-clinical-trials","title":"Bayesian Designs for Phase I-II Clinical Trials","description":"\u003cp\u003eReliably optimizing a new treatment in humans is a critical first step in clinical evaluation since choosing a suboptimal dose or schedule may lead to failure in later trials. At the same time, if promising preclinical results do not translate into a real treatment advance, it is important to determine this quickly and terminate the clinical evaluation process to avoid wasting resources. \u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eBayesian Designs for Phase I–II Clinical Trials\u003c\/strong\u003e describes how phase I–II designs can serve as a bridge or protective barrier between preclinical studies and large confirmatory clinical trials. It illustrates many of the severe drawbacks with conventional methods used for early-phase clinical trials and presents numerous Bayesian designs for human clinical trials of new experimental treatment regimes.\u003c\/p\u003e\u003cp\u003eWritten by research leaders from the University of Texas MD Anderson Cancer Center, this book shows how Bayesian designs for early-phase clinical trials can explore, refine, and optimize new experimental treatments. It emphasizes the importance of basing decisions on both efficacy and toxicity. \u003c\/p\u003e","brand":"Taylor \u0026 Francis","offers":[{"title":"Default Title","offer_id":45541961990382,"sku":"9781032242644","price":67.19,"currency_code":"AUD","in_stock":true}],"url":"https:\/\/bookland.com.au\/products\/bayesian-designs-for-phase-i-ii-clinical-trials","provider":"Book Land AU","version":"1.0","type":"link"}